Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update
March 17, 2022 06:30 ET
|
Liquidia Corporation
- Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administration - Preparing to launch YUTREPIA in...
Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022
March 10, 2022 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., March 10, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2021 financial results on Thursday, March 17, 2022. The...
Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2022 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of...
Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million
January 07, 2022 09:02 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which...
Liquidia Corporation Announces Chief Executive Officer Transition
January 03, 2022 16:52 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022...
Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation
December 29, 2021 06:45 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with...
Liquidia to Participate in the Jefferies London Healthcare Conference
November 11, 2021 16:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the...
FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder
November 08, 2021 05:45 ET
|
Liquidia Corporation
First dry-powder formulation of treprostinil to meet criteria required for FDA approvalFinal FDA approval may occur in October 2022 or earlier upon resolution of on-going litigationConference call and...
Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 03, 2021 16:55 ET
|
Liquidia Corporation
- Increased adoption of generic Treprostinil Injection by patients, physicians and payers- Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities- Anticipate FDA...
Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
October 08, 2021 17:23 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes...